Description
Sotorasib
EACH LUCISOT TABLET CONTAINS
Sotorasib … 120mg
INDICATION
LuciSot is an inhibitor of the RAS GTPase family indicated for the treatment of adult patients, with KRAS G12C -mutated locally advanced or metastatic non -small cell lung cancer (NSCLC), as determined by an FDA -approved test, who have received at least one prior systemic therapy.
DOSAGE AND USE
The recommended dosage of LuciSot is 960 mg (eight 120 mg tablets) orally once daily until disease progression or unacceptable toxicity. Take LuciSot at the same time each day with or without food. Recommended LuciSot Dose Reduction Levels for Adverse Reactions: • First dose reduction: 480 mg (4 tablets) once daily • Second dose reduction: 240 mg (2 tablets) once daily • Tablets should be swallowed whole & not chewed or crushed.
STORAGE
Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F). Keep medicine out of the reach of Children.
MANUFACTURED AND MARKETED BY
LUCIUS PHARMACEUTICALS(LAO) CO., LTD No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos
WARNING AND PRECAUTION
To be sold by retail on prescription of a Registered oncologist only, and as directed by the physician
Reviews
There are no reviews yet.